VPO Exhibitor - About Us

No contacts to display.

News Releases

Jun 30, 2026

Aspen Neuroscience Announces Completion of Cohort 3 and 4 Dosing in Aspiro Phase 1/2a Trial of Sasineprocel for Parkinson's Disease

Advancement of commercial-ready formulation supports scalability and late-stage development SAN DIEGO, June 30, 2026 /PRNewswire/ -- Aspen Neuroscience, Inc., a clinical-stage regenerative...

Jun 11, 2026

Aspen Neuroscience Appoints Jeff Boerneke as General Counsel and Secretary

Experienced biotech legal executive strengthens leadership team as Aspen advances clinical development and prepares for Phase 3 growth SAN DIEGO, June 11, 2026 /PRNewswire/ -- Aspen Neuroscience,...

Mar 18, 2026

Aspen Neuroscience Announces Positive 12‑Month Data from its ASPIRO Clinical Trial in a Late‑Breaking Oral Presentation at the AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases

Results Show Continued Safety, Tolerability, and Sustained Clinical Benefit Including Improvements in Function, Physician- and Patient-Reported Outcomes, and Quality-of-Life This Personalized...

Mar 12, 2026

Aspen Receives Adoption of Sasineprocel as the Official Nonproprietary Naming of ANPD001, its Investigational Autologous Cell Therapy for the Treatment of Parkinson's Disease

Approved for Use By both the World Health Organization's International Nonproprietary Names (WHO-INN) and the American Medical Association's United States Adopted Names (AMA-USAN) Council SAN...

Jan 8, 2026

Aspen Neuroscience Completes Phase 1/2a ASPIRO Trial Cohort Three Dosing and State-of-the-Art Manufacturing Expansion, Paving the Way for Developing Transformative Therapies for Patients

Facility Enters Qualification to Support Late‑Stage Pivotal Manufacturing and Commercial Readiness SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Aspen Neuroscience, Inc., a clinical‑stage...